Synageva BioPharma (GEVA)

[surf1944]

Synageva BioPharma to Host 2011 Fourth Quarter and Full Year Financial Results Conference Call on March 15
Business WirePress Release: Synageva BioPharma Corp. – Thu, Mar 8, 2012 4:05 PM EST

LEXINGTON, Mass.--(BUSINESS WIRE)--

Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA - News), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, will report 2011 fourth quarter and full year financial results after the NASDAQ Market closes on Thursday, March 15, 2012. Synageva management will conduct a conference call and audio webcast to discuss clinical development progress and financial results at 4:30 pm EDT on the same day.

The dial-in number for the conference call is 866-578-5784. The conference ID for callers is 74850064. A live webcast of the call will be available from the “Webcasts & Presentations” section of the Investor Relations tab on the home page of Synageva’s website at www.synageva.com.

About Synageva’s Lead Program

SBC-102 is being developed as an enzyme replacement for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme. SBC-102 is currently being evaluated in global clinical trials and has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency. Additionally, SBC-102 received fast track designation by the FDA.